Desferrioxamine suppresses experimental allergic encephalomyelitis induced by MBP in SJL mice
The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Abstract
Data from several studies indicate that free radicals have a pathogenic role in experimental allergic encephalomyelitis (EAE). Iron can contribute to free radical damage by catalyzing the formation of hydroxyl radical, inducing secondary initiation of lipid peroxidation and by promoting the oxidation of proteins. The iron chelator, desferrioxamine, can limit these oxidative reactions and it can scavenge peroxynitrite independent of iron chelation. Two previous studies have examined the therapeutic value of desferrioxamine in EAE. One study observed an effect when disease was induced by spinal cord homogenates (J. Exp. Med. 160, p. 1532, 1984), but a second study found no therapeutic value of desferrioxamine for myelin basic protein (MBP)-induced EAE (J. Neuroimmunol. 17, p. 127, 1988). In the second study, the drug was only administered during the preclinical stages of disease. Since desferrioxamine scavenges free radicals and prevents their formation, we hypothesized that the drug should be given during the active stage of disease to have therapeutic value. We first demonstrated that the drug enters the CNS around inflammatory cells in EAE animals. In animals treated during the active stage of MBP-induced EAE, the clinical signs were significantly reduced compared to vehicle-treated animals. The iron-bound form of this drug, ferrioxamine, was without therapeutic value. A derivative of desferrioxamine, hydroxylethyl starch (HES)-desferrioxamine, has a greater plasma half-life than desferrioxamine and it was also tested. Although there was a suggestion of improvement in these animals, the effects were less than that observed for desferrioxamine which may be related to the greater molecular size of HES-desferrioxamine. In summary, these data suggest that chelation of iron is an effective therapeutic target for EAE.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“iron chelators have been shown to suppress disease progression in experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis”
From Towards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson’s, Huntington’s, Alzheimer’s, prions, bactericides, chemical toxicology and others as examples (2010) · cites this paper as Pedchenko and LeVine 1998
Citations
Cites
Beckman, J. S., Beckman, T. W., Chen, J., Marshall, P. A., & Freeman, B. A. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.4.1620 · Cited by 7,029
Oxygen toxicity, oxygen radicals, transition metals and disease
Halliwell, B., & Gutteridge, J. M. C. (1984) · Biochemical Journal · doi:10.1042/bj2190001 · Cited by 5,330
Metal ion-catalyzed oxidation of proteins: Biochemical mechanism and biological consequences
Stadtman, E. R. (1990) · Free Radical Biology and Medicine · doi:10.1016/0891-5849(90)90006-5 · Cited by 1,153
Metal-catalyzed oxidation of proteins. Physiological consequences
Stadtman, E. R., & Oliver, C. N. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)52199-2 · Cited by 862
The regional distribution and cellular localization of iron in the rat brain
Hill, J. M., & Switzer, R. C. (1984) · Neuroscience · doi:10.1016/0306-4522(84)90046-0 · Cited by 486
Cellular distribution of transferrin, ferritin, and iron in normal and aged human brains
Connor, J. R., Menzies, S. L., Martin, S. M. S., & Mufson, E. J. (1990) · Journal of Neuroscience Research · doi:10.1002/jnr.490270421 · Cited by 472
Cross, A. H., Misko, T. P., Lin, R. F., Hickey, W. F., Trotter, J. L., & Tilton, R. G. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117282 · Cited by 384 · cited 1×
“: q1 913 5887420; fax: q1 913 5885677; e-mail: slevine@kumc.edu Žmation suppress EAE Cross et al., 1994; Ruuls et al., .1995; Zhao et al., 1996 .”
Ferritin as a source of iron for oxidative damage
Reif, D. W. (1992) · Free Radical Biology and Medicine · doi:10.1016/0891-5849(92)90091-t · Cited by 357 · cited 1×
“The first two Žmolecules can release iron from ferritin Reif and Sim.mons, 1990; Reif, 1992 .”
BackgroundNitric oxide mediates iron release from ferritin
Reif, D. W., & Simmons, R. D. (1990) · Archives of Biochemistry and Biophysics · doi:10.1016/0003-9861(90)90680-w · Cited by 278
Iron deposits in multiple sclerosis and Alzheimer's disease brains
LeVine, S. M. (1997) · Brain Research · doi:10.1016/s0006-8993(97)00470-8 · Cited by 258
Self-citation
Research works printed but not linked: 1
- Tangoren, 1991, Reducing brain edema in experimental concussive brain injury with post-injury treatment by polysaccharide–desferrioxamine, Soc. Neurosci. Abstr., 17, 163
Cited by
Demyelination: The Role of Reactive Oxygen and Nitrogen Species
Smith, K. J., Kapoor, R., & Felts, P. A. (1999) · Brain Pathology · doi:10.1111/j.1750-3639.1999.tb00212.x · Cited by 600
“However, a recent finding has found a reduction in clinical signs when animals were treated with desferrioxamine during the active stage of MBP-induced disease (172) .”
BackgroundKell, D. B. (2010) · Archives of Toxicology · doi:10.1007/s00204-010-0577-x · Cited by 361
“…dysregulation in MS is not yet established, it is highly pertinent that iron chelators have been shown to suppress disease progression in experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis (Bowern et al. 1984; Mitchell et al. 2007; Pedchenko and LeVine 1998).”
BackgroundIron in Chronic Brain Disorders: Imaging and Neurotherapeutic Implications
Stankiewicz, J., Panter, S. S., Neema, M., Arora, A., Batt, C. E., & Bakshi, R. (2007) · Neurotherapeutics · doi:10.1016/j.nurt.2007.05.006 · Cited by 301
“Postulating that DES scavenges and prevents free radical formation, and consequently will only be efficacious during active disease, Pedchenko et al.(119) treated rats in the active stage of EAE and observed significantly reduced clinical signs when compared to vehicle-treated animals.”
ResultWhat Is Responsible for the Initiating Chemistry of Iron-Mediated Lipid Peroxidation: An Update
Cheng, Z., & Li, Y. (2007) · Chemical Reviews · doi:10.1021/cr040077w · Cited by 211
Sheikh, S., Safia, Haque, E., & Mir, S. S. (2013) · Journal of Neurodegenerative Diseases · doi:10.1155/2013/563481 · Cited by 189
“e iron chelator, deferoxamine, can limit these oxidative reactions and it scavenges the peroxynitrite independent of iron chelation [36] becausewith deferoxamine the iron can be rebound to the lesions.”
Background
Metadata
- Authors
- Pedchenko, T. V., & LeVine, S. M.
- Affiliations
- University of Kansas Medical Center (US)
- ORCID
- LeVine, Steven M
- Venue
- Journal of Neuroimmunology
- Publisher
- Elsevier BV
- Published
- 1998-04
- Volume
- 84
- Issue
- 2
- Pages
- 188-197
- ISSN
- 0165-5728 (ISSN-L)
- OpenAlex
- W2030389778
- Cited by
- 78
- References
- 44
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 4 · 2023: 2 · 2022: 3 · 2021: 2 · 2020: 2 · 2019: 3 · 2018: 3 · 2017: 1 · 2015: 1 · 2014: 5 · 2012: 7
- FWCI
- 1.97
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- Journal of Neuroimmunology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5r01ns033596-03)
- National Institute of Neurological Disorders and Stroke (NS 33596)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (HD-02528)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
- Health Sciences › Medicine › Clinical Neurology › Peripheral Neuropathies and Disorders
- Health Sciences › Medicine › Biochemistry (medical) › Antioxidant Activity and Oxidative Stress
- Keywords
- deferoxamine, experimental autoimmune encephalomyelitis, myelin basic protein, iron chelation, free radicals, hydroxyl radicals, lipid peroxidation, peroxynitrite scavenging, ferrioxamine, SJL mice, multiple sclerosis treatment
- MeSH terms
- Animals, Deferoxamine, Demyelinating Diseases, Myelin Basic Protein, Encephalomyelitis, Autoimmune, Experimental, Ferric Compounds, Free Radicals, Hydroxyethyl Starch Derivatives, Immunohistochemistry, Iron, Iron Chelating Agents, Male, Mice, Inbred Strains, Myelin Sheath, Tissue Distribution, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Desferrioxamine suppresses experimental allergic encephalomyelitis induced by MBP in SJL mice. https://app.cochat.ai/papers/10.1016/s0165-5728(97)00256-7
- The paper
- Pedchenko, T. V., & LeVine, S. M. (1998). Desferrioxamine suppresses experimental allergic encephalomyelitis induced by MBP in SJL mice. Journal of Neuroimmunology. https://doi.org/10.1016/s0165-5728(97)00256-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.